Please use this identifier to cite or link to this item:
Title: Will delays from the coronavirus pandemic affect localised prostate cancer outcomes?
Epworth Authors: Ong, Sean
Bagguley, Dominic
Murphy, Declan
Lawrentschuk, Nathan
Keywords: COVID-19
Localised Prostate Cancer
Decision Making
Patient Safety
Delayed Treatment
Favourable Risk
Unfavourable Risk
E.J. Whitten Foundation Prostate Cancer Research Centre at Epworth, Epworth HealthCare, Melbourne, Australia
Issue Date: Oct-2020
Conference Name: Epworth HealthCare Research Month 2020
Conference Location: Epworth Research Institute, Victoria, Australia
Abstract: The global coronavirus (COVID-19) pandemic presents a unique situation whereby governing bodies seek to balance the risks of deferring treatment with the preservation of hospital resources. For the moment, there are no widely accepted “COVID-19 era” management guidelines for patients with prostate cancer. Many difficult decisions need to be made on a case by case basis, bearing in mind hospital capabilities, disease risk, patient factors and of course patients’ mental health and anxiety. For prostate cancer, urology teams will need to manage an already overcrowded list of patients needing radical prostatectomies. Fortunately, the literature demonstrates that delays of up to 12 months with no ADT are not associated with adverse outcomes post operatively for all categories of localised prostate cancer.
Type: Conference Poster
Affiliated Organisations: Department of Urology, Peter MacCallum Cancer Centre, Melbourne, Australia
Department of Urology, Royal Melbourne Hospital, Melbourne, Australia
Type of Clinical Study or Trial: Literature Review
Appears in Collections:Research Month

Files in This Item:
File Description SizeFormat  
Ong, Sean_Delays in RP during COVID - Epworth poster (1).pdf724.35 kBAdobe PDFThumbnail

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.